Shares in Novo Nordisk fell sharply after the announcement. However, that was likely driven by news that Wegovy and two other semaglutide products – Ozempic and Rybelsus for type 2 diabetes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback